

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
03 October 2024 (03.10.2024)



(10) International Publication Number
WO 2024/206647 A1

- (51) **International Patent Classification:**
A61K 31/425 (2006.01) *A61K 31/44* (2006.01)
- (21) **International Application Number:**
PCT/US2024/021994
- (22) **International Filing Date:**
28 March 2024 (28.03.2024)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
PCT/CN2023/084794
29 March 2023 (29.03.2023) CN
- (71) **Applicants: TERNS PHARMACEUTICALS, INC.** [US/US]; 1065 E. Hillsdale Blvd., Suite 100, Foster City, California 94404 (US). **TERNS (SUZHOU) BIOTECHNOLOGY CO., LTD.** [CN/CN]; Unit E328, Floor 2, North Block, Building A1, Biopharmaceutical Industrial Park, No.218 of Xing Hu Street, Suzhou Industrial Park, Suzhou, Jiangsu 215125 (CN).
- (72) **Inventors; and**
- (71) **Applicants: BIAN, Jianwei** [CN/US]; c/o Terns Pharmaceuticals, Inc., 1065 E. Hillsdale Blvd., Suite 100, Foster

City, California 94404 (US). **CAI, Chunlong** [CN/US]; c/o Terns Pharmaceuticals, Inc., 1065 E. Hillsdale Blvd., Suite 100, Foster City, California 94404 (US). **CHOU, Lu A.** [CN/US]; c/o Terns, Inc., 1065 E. Hillsdale Blvd., Suite 100, Foster City, California 94404 (US).

(74) **Agent: MANSON, Daniel E.** et al.; Cooley LLP, 1299 Pennsylvania Avenue NW, Suite 700, Washington, District of Columbia 20004 (US).

(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,

(54) **Title:** POLYMORPHIC FORMS AND SALTS OF A GLP-1R AGONIST




FIG. 1

(57) **Abstract:** The disclosure relates to solid forms of 2-((4-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)piperidin-1-yl)methyl)-1-(thiazol-5-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid (Compound 1), including solid forms of Compound 1, salts of Compound 1 and solid forms thereof, including crystalline forms of Compound 1 and salts thereof, as well as polymorphs of Compound 1 and salts of Compound 1.

[Continued on next page]

WO 2024/206647 A1

SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*